$IMCR Income Statement | Understand Stock

$IMCR

$31.96 +$0.68 (2.17%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Product revenue, net
Pre-product revenue, net
Total revenue from sale of therapies
Revenue:
Product Revenue, Net
Pre-Product Revenue
Revenue from sale of therapies, net
Collaboration revenue
Total revenue
Cost of product revenue
Net other operating income/ (loss)
Research and development costs
Administrative expenses
Selling and administrative expenses
Operating loss
Finance income
Finance costs
Non-operating expense
Loss before taxation
Income tax credit
Loss for the year
Exchange differences on translation of foreign operations
Total comprehensive loss for the year, net of tax
Basic loss per share (in pounds per share)

Cost and operating expenses:
Cost of revenue from sale of therapies
Research and development expense
Selling, general and administrative expense
Loss from operations
Other income (expense):
Interest income
Interest expense
Foreign currency gain (loss)
Other income (expense), net
Net loss before income taxes
Income tax (expense) benefit
Net loss
Other comprehensive income:
Exchange differences on translation of foreign operations
Total comprehensive loss
Basic net loss per share (in dollars per share)
Diluted net loss per share (in dollars per share)
Basic weighted-average number of shares outstanding (in shares)
Diluted weighted-average number of shares outstanding (in shares)

Comments